Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Working Capital Changes (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Other Working Capital Changes for 16 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 63.43% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.1 million through Dec 2025, up 77.04% year-over-year, with the annual reading at $12.1 million for FY2025, 77.04% up from the prior year.
  • Other Working Capital Changes hit $5.9 million in Q4 2025 for Vanda Pharmaceuticals, up from -$703000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $13.4 million in Q1 2022 to a low of -$11.3 million in Q1 2023.
  • Historically, Other Working Capital Changes has averaged $887150.0 across 5 years, with a median of $1.3 million in 2021.
  • Biggest YoY gain for Other Working Capital Changes was 26820.0% in 2022; the steepest drop was 398.11% in 2022.
  • Year by year, Other Working Capital Changes stood at -$1.7 million in 2021, then crashed by 104.57% to -$3.4 million in 2022, then crashed by 108.59% to -$7.2 million in 2023, then surged by 150.58% to $3.6 million in 2024, then skyrocketed by 63.43% to $5.9 million in 2025.
  • Business Quant data shows Other Working Capital Changes for VNDA at $5.9 million in Q4 2025, -$703000.0 in Q3 2025, and $1.4 million in Q2 2025.